COVID-19 in South Dakota: 401 total new cases; Death toll rises to 2,167; Active cases at 6,735

Health

KELOLAND.com 06 October, 2021 - 10:24am 6 views

We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.

Be the first to rate this article

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected during an outbreak in late 2019 in Wuhan, China. Since the emergence of this virus, the original strain has been supplanted by several variants, which have arisen from a variety of mutations. The Spike (S) protein of the virus is the location at which several of these mutations have occurred, which has given many variants the ability to evade the neutralizing antibody response.

The subunits S1 and S2 make up the SARS-CoV-2 S protein. The S1 subunit comprises the receptor-binding domain (RBD) and the N-terminal domain (NTD). The RBD interacts with the angiotensin-converting enzyme 2 (ACE2) receptor and is the primary target for neutralizing antibodies. The functions of the NTD are not yet fully understood, but it is hypothesized that it may be associated with receptor recognition, glycan-binding, and pre-fusion-to-post-fusion conformational changes.

Researchers compared the replication and syncytia forming potential of Alpha, Beta, and D614G strains in human cell lines and primary airway cells. The authors also characterized the fusogenicity of the Alpha and Beta variants' S proteins and the contributions of each mutation in syncytia formation, ACE2 binding, and evasion of neutralizing antibodies. Finally, the authors analyzed the syncytia forming potential and ACE2 binding capacity of the Delta variant S protein.

A preprint* version of the study is available while the article undergoes peer review.

The authors utilized an S-Fuse assay using U2OS-ACE2 GFP-split cells to induce syncytia in potential SARS-CoV-2 variants. The Alpha and Beta variants formed more numerous and larger infected syncytia upon infection of S-Fuse cells compared to both the original Wuhan strain and the D146G strain. By calculating the total syncytia area and then normalizing the nuclei number, the authors quantitatively characterized the differences in fusogenicity.

Significantly more syncytia were produced by the Alpha and Beta variants, relative to D614G, approximately 4.5 and 3-fold respectively, after 20 hours of infection with the same multiplicity of infection (MOI). Vero cells carrying the GFP-split system were generated to characterize syncytia formation in a cell line expressing endogenous ACE2.

Following 48 hours of infection with the same MOI, Alpha and Beta variants were still found to have produced significantly more syncytia when compared to D614G, which suggests that the Alpha and Beta variants are more fusogenic.

The Alpha, Beta, and D614G variants are all affected differently by certain neutralizing antibodies. For example, the D614G variant is restricted by the neutralizing monoclonal antibody 48 (mAb48), but the Alpha and Beta variants are not. The authors determined which mutations in S protein variants contributed to the reduced recognition by neutralizing antibodies by utilizing flow cytometry to observe the binding of a panel of four monoclonal antibodies (mAbs) to different mutants of S proteins.

MAb48 did not recognize the Alpha and Beta variants, and it also did not bind to the K417N mutant. The Alpha and Beta variants were also not recognized by mAb71 and did not bind to their NTD ΔY144 and Δ242-244 mutations. A decrease in S-mediated fusion is caused by the mutations Δ242-244 and K417N, which suggests a trade-off between antibody escape and fusion.

The Beta variant was not recognized by mAb98, although the lack of binding was not a consequence of the associated mutations. This suggests antibody escape may be affected by a combined effect on the structure of the S protein. Therefore, despite a reduction in protein fusion ability, several mutations found in the S proteins of variants are advantageous in escaping antibodies.

In this study, the authors characterized the replication, antibody recognition, fusogenicity, and ACE2 binding of the Alpha and Beta variants of SARS-CoV-2 and the role of S-associated mutations. The authors detailed insights into the S-mediated fusogenicity of the variants but did not examine the conformational changes that individual mutations or a combination of mutations may elicit.

Furthermore, the authors show when compared to the D614G variant, the S proteins of the Alpha, Beta, and Delta variants bind to ACE2 more efficiently and are more fusogenic. The answer to why the Delta variant elicits higher transmissibility rates was not answered within this study and should be addressed in future work.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.

Be the first to rate this article

Posted in: Medical Science News | Medical Research News | Disease/Infection News

Tags: ACE2, Angiotensin, Angiotensin-Converting Enzyme 2, Antibodies, Antibody, Assay, Cell, Cell Line, Coronavirus, Coronavirus Disease COVID-19, Cytometry, Enzyme, Flow Cytometry, Glycan, Monoclonal Antibody, Mutation, Protein, Receptor, Respiratory, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Syndrome, Virus

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

Please use one of the following formats to cite this article in your essay, paper or report:

Lightfoot, Colin. (2021, October 06). SARS-CoV-2 emerging variants display enhanced syncytia formation. News-Medical. Retrieved on October 06, 2021 from https://www.news-medical.net/news/20211006/SARS-CoV-2-emerging-variants-display-enhanced-syncytia-formation.aspx.

Lightfoot, Colin. "SARS-CoV-2 emerging variants display enhanced syncytia formation". News-Medical. 06 October 2021. <https://www.news-medical.net/news/20211006/SARS-CoV-2-emerging-variants-display-enhanced-syncytia-formation.aspx>.

Lightfoot, Colin. "SARS-CoV-2 emerging variants display enhanced syncytia formation". News-Medical. https://www.news-medical.net/news/20211006/SARS-CoV-2-emerging-variants-display-enhanced-syncytia-formation.aspx. (accessed October 06, 2021).

Lightfoot, Colin. 2021. SARS-CoV-2 emerging variants display enhanced syncytia formation. News-Medical, viewed 06 October 2021, https://www.news-medical.net/news/20211006/SARS-CoV-2-emerging-variants-display-enhanced-syncytia-formation.aspx.

News-Medical speaks to Dr. Yana Vinogradova about her latest research into menopausal hormone therapy (MHT) and its unassociated risk to dementia.

In this interview, News-Medical speaks to Dr. Satchin Panda about his latest research into time-restricted eating and how it can be used to manage metabolic diseases.

In this interview, News-Medical talks to Patrick Gilbert, Technical Director at Purolite, about the work Purolite do and how their chemical synthesis processes are benefitted by the Radleys Mya 4 reaction station.

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Owned and operated by AZoNetwork, © 2000-2021

Read full article at KELOLAND.com

Health Stories

JCPenney